FDA Approves Tucatinib as Maintenance Therapy for HER2-Positive Breast Cancer — MD /Alert Exclusive

FDA Approves Tucatinib as Maintenance Therapy for HER2-Positive Breast Cancer

FDA Approves Palbociclib With Trastuzumab for HR-Positive, HER2-Positive MBC — MD /Alert Exclusive

FDA Approves Palbociclib With Trastuzumab for HR-Positive, HER2-Positive MBC

Real-World Analysis Suggests Lower Brain Metastasis Risk With T-DXd vs TTC in Patients With HER2+ Metastatic Breast Cancer — LIVE FROM ASCO

Real-World Analysis Suggests Lower Brain Metastasis Risk With T-DXd vs TTC in Patients With HER2+ Metastatic Breast Cancer

Rilvegostomig Plus Trastuzumab Deruxtecan Allows Certain Patients to Skip Breast Cancer Chemotherapy — LIVE FROM ASCO

Rilvegostomig Plus Trastuzumab Deruxtecan Allows Certain Patients to Skip Breast Cancer Chemotherapy

Sacituzumab Govitecan Improves PFS2 in Patients With Previously Untreated TNBC — LIVE FROM ASCO

Sacituzumab Govitecan Improves PFS2 in Patients With Previously Untreated TNBC

Recommended

FDA Approves Tucatinib as Maintenance Therapy for HER2-Positive Breast Cancer

FDA Approves Tucatinib as Maintenance Therapy for HER2-Positive Breast Cancer

FDA Approves Palbociclib With Trastuzumab for HR-Positive, HER2-Positive MBC

FDA Approves Palbociclib With Trastuzumab for HR-Positive, HER2-Positive MBC

Real-World Analysis Suggests Lower Brain Metastasis Risk With T-DXd vs TTC in Patients With HER2+ Metastatic Breast Cancer

Real-World Analysis Suggests Lower Brain Metastasis Risk With T-DXd vs TTC in Patients With HER2+ Metastatic Breast Cancer

Rilvegostomig Plus Trastuzumab Deruxtecan Allows Certain Patients to Skip Breast Cancer Chemotherapy

Rilvegostomig Plus Trastuzumab Deruxtecan Allows Certain Patients to Skip Breast Cancer Chemotherapy

Sacituzumab Govitecan Improves PFS2 in Patients With Previously Untreated TNBC

Sacituzumab Govitecan Improves PFS2 in Patients With Previously Untreated TNBC

Tucatinib Extends PFS Across Key Subgroups in Patients With HER2+ Metastatic Breast Cancer

Tucatinib Extends PFS Across Key Subgroups in Patients With HER2+ Metastatic Breast Cancer

Axillary Lymph Node Dissection Can Be Omitted Safely in Breast Cancer Patients With Macrometastases

Axillary Lymph Node Dissection Can Be Omitted Safely in Breast Cancer Patients With Macrometastases

Giredestrant Highly Effective in Early Breast Cancer, Regardless of Menopausal Status

Giredestrant Highly Effective in Early Breast Cancer, Regardless of Menopausal Status

Weight-Loss Intervention Improves Physical Functioning, Quality of Life in Breast Cancer

Weight-Loss Intervention Improves Physical Functioning, Quality of Life in Breast Cancer

Bireociclib, Fulvestrant Improve PFS After Endocrine Therapy in Advanced Breast Cancer

Bireociclib, Fulvestrant Improve PFS After Endocrine Therapy in Advanced Breast Cancer

Exemestane Less Effective Than Other Aromatase Inhibitors for Postmenopausal BC Patients

Exemestane Less Effective Than Other Aromatase Inhibitors for Postmenopausal BC Patients

DESTINY-Breast11 Safety Analysis: Trastuzumab Deruxtecan Demonstrates Favorable Adverse Event Outcomes

DESTINY-Breast11 Safety Analysis: Trastuzumab Deruxtecan Demonstrates Favorable Adverse Event Outcomes

AI Tool Improves Accuracy, Reduces Equivocal Results in HER2 Breast Cancer Scoring

AI Tool Improves Accuracy, Reduces Equivocal Results in HER2 Breast Cancer Scoring

Extended Adjuvant Endocrine Therapy Improves Outcomes in BRCA Carriers

Extended Adjuvant Endocrine Therapy Improves Outcomes in BRCA Carriers

Imlunestrant, Abemaciclib Improve OS in Patients With Advanced Breast Cancer

Imlunestrant, Abemaciclib Improve OS in Patients With Advanced Breast Cancer

Certain Adverse Events Predict Complete Response in Early Breast Cancer

Certain Adverse Events Predict Complete Response in Early Breast Cancer

Parity and Breastfeeding Confer T-Cell Protection Against Breast Cancer

Parity and Breastfeeding Confer T-Cell Protection Against Breast Cancer

SABCS: Phase 3 Studies Set to Reshape Breast Cancer Care

SABCS: Phase 3 Studies Set to Reshape Breast Cancer Care

Know Before You Go: SABCS 2025

Know Before You Go: SABCS 2025

Adjuvant Chemotherapy Offers No Survival Benefit for Older Patients With Breast Cancer

Adjuvant Chemotherapy Offers No Survival Benefit for Older Patients With Breast Cancer

Black, Latinx, and Asian Women Less Likely to Receive Biomarker Testing Following Metastatic Breast Cancer Diagnosis

Black, Latinx, and Asian Women Less Likely to Receive Biomarker Testing Following Metastatic Breast Cancer Diagnosis

Elacestrant May Offer ‘Endocrine Therapy Backbone’ in ER+/ HER2- Breast Cancer

Elacestrant May Offer ‘Endocrine Therapy Backbone’ in ER+/ HER2- Breast Cancer

Sacituzumab Govitecan, Pembrolizumab Effective for Early Triple-Negative Breast Cancer

Sacituzumab Govitecan, Pembrolizumab Effective for Early Triple-Negative Breast Cancer

Model Predicts Future Risk of Breast Cancer Following ER+/HER2- Breast Cancer

Model Predicts Future Risk of Breast Cancer Following ER+/HER2- Breast Cancer

Combination Inavolisib, Palbociclib, Fulvestrant Boosts Survival for PIK3CA-Mutated HR+, HER2-, Endocrine-Resistant Advanced Breast Cancer

Combination Inavolisib, Palbociclib, Fulvestrant Boosts Survival for PIK3CA-Mutated HR+, HER2-, Endocrine-Resistant Advanced Breast Cancer

Ribociclib, Trastuzumab, Letrozole Combination Extends Survival in HR+/ HER2+ Advanced Breast Cancer

Ribociclib, Trastuzumab, Letrozole Combination Extends Survival in HR+/ HER2+ Advanced Breast Cancer

Artificial Intelligence Training Platform Aids in Better HER2 Immunohistochemistry Scoring

Artificial Intelligence Training Platform Aids in Better HER2 Immunohistochemistry Scoring

Certain Patients with Invasive Breast Cancer Can Achieve Long-Term Disease Control Without Surgery

Certain Patients with Invasive Breast Cancer Can Achieve Long-Term Disease Control Without Surgery

FDA Approves Trastuzumab Deruxtecan in Earlier Line of HER2-low, Ultralow Breast Cancer

FDA Approves Trastuzumab Deruxtecan in Earlier Line of HER2-low, Ultralow Breast Cancer

Researchers Address Potential Cardiotoxicity Concerns of Aromatase Inhibitors in Early Breast Cancer

Researchers Address Potential Cardiotoxicity Concerns of Aromatase Inhibitors in Early Breast Cancer

Sacituzumab Govitecan Improves Outcomes for Pretreated Triple-Negative Breast Cancer

Sacituzumab Govitecan Improves Outcomes for Pretreated Triple-Negative Breast Cancer

ASCO, SSO Publish Guidelines for Germline Mutation Testing in Breast Cancer

ASCO, SSO Publish Guidelines for Germline Mutation Testing in Breast Cancer

Fertility Preservation Safe for Patients Who Pause HR-positive Breast Cancer Endocrine Therapy to Conceive

Fertility Preservation Safe for Patients Who Pause HR-positive Breast Cancer Endocrine Therapy to Conceive

Younger Postmenopausal Patients May Skip Adjuvant Radiotherapy After Early Breast Cancer Surgery

Younger Postmenopausal Patients May Skip Adjuvant Radiotherapy After Early Breast Cancer Surgery

Patients with Breast Cancer That Converts from Lymph Node-Positive to -Negative Can Skip Adjuvant Irradiation

Patients with Breast Cancer That Converts from Lymph Node-Positive to -Negative Can Skip Adjuvant Irradiation

Tucatinib Plus Trastuzumab Emtansine Extend PFS in Late-Stage HER2-Positive Breast Cancer

Tucatinib Plus Trastuzumab Emtansine Extend PFS in Late-Stage HER2-Positive Breast Cancer

Pertuzumab, Trastuzumab Combination Effective in HER2+ Metastatic Breast Cancer

Pertuzumab, Trastuzumab Combination Effective in HER2+ Metastatic Breast Cancer

Sacituzumab Govitecan Improves OS in Endocrine-Resistant Metastatic Breast Cancer

Sacituzumab Govitecan Improves OS in Endocrine-Resistant Metastatic Breast Cancer

PET-CT Scanning Improves Detection of Metastases in Patients With Locally Advanced Breast Cancer

PET-CT Scanning Improves Detection of Metastases in Patients With Locally Advanced Breast Cancer

NCCN Clinical Practice Guidelines Recommend FES PET Imaging for ER+ Breast Cancer

NCCN Clinical Practice Guidelines Recommend FES PET Imaging for ER+ Breast Cancer

Metastatic Breast Cancer: 'The Journey Begins'

Metastatic Breast Cancer: "The Journey Begins"

ASCO 2026 Annual Meeting

Rilvegostomig Plus Trastuzumab Deruxtecan Allows Certain Patients to Skip Breast Cancer Chemotherapy

Rilvegostomig Plus Trastuzumab Deruxtecan Allows Certain Patients to Skip Breast Cancer Chemotherapy

Real-World Analysis Suggests Lower Brain Metastasis Risk With T-DXd vs TTC in Patients With HER2+ Metastatic Breast Cancer

Real-World Analysis Suggests Lower Brain Metastasis Risk With T-DXd vs TTC in Patients With HER2+ Metastatic Breast Cancer

Tucatinib Extends PFS Across Key Subgroups in Patients With HER2+ Metastatic Breast Cancer

Tucatinib Extends PFS Across Key Subgroups in Patients With HER2+ Metastatic Breast Cancer

Sacituzumab Govitecan Improves PFS2 in Patients With Previously Untreated TNBC

Sacituzumab Govitecan Improves PFS2 in Patients With Previously Untreated TNBC

Axillary Lymph Node Dissection Can Be Omitted Safely in Breast Cancer Patients With Macrometastases

Axillary Lymph Node Dissection Can Be Omitted Safely in Breast Cancer Patients With Macrometastases

Giredestrant Highly Effective in Early Breast Cancer, Regardless of Menopausal Status

Giredestrant Highly Effective in Early Breast Cancer, Regardless of Menopausal Status

Weight-Loss Intervention Improves Physical Functioning, Quality of Life in Breast Cancer

Weight-Loss Intervention Improves Physical Functioning, Quality of Life in Breast Cancer

SABCS 2025 Annual Meeting

DESTINY-Breast11 Safety Analysis: Trastuzumab Deruxtecan Demonstrates Favorable Adverse Event Outcomes

DESTINY-Breast11 Safety Analysis: Trastuzumab Deruxtecan Demonstrates Favorable Adverse Event Outcomes

AI Tool Improves Accuracy, Reduces Equivocal Results in HER2 Breast Cancer Scoring

AI Tool Improves Accuracy, Reduces Equivocal Results in HER2 Breast Cancer Scoring

Extended Adjuvant Endocrine Therapy Improves Outcomes in BRCA Carriers

Extended Adjuvant Endocrine Therapy Improves Outcomes in BRCA Carriers

Imlunestrant, Abemaciclib Improve OS in Patients With Advanced Breast Cancer

Imlunestrant, Abemaciclib Improve OS in Patients With Advanced Breast Cancer

Certain Adverse Events Predict Complete Response in Early Breast Cancer

Certain Adverse Events Predict Complete Response in Early Breast Cancer

SABCS: Phase 3 Studies Set to Reshape Breast Cancer Care

SABCS: Phase 3 Studies Set to Reshape Breast Cancer Care

Know Before You Go: SABCS 2025

Know Before You Go: SABCS 2025

MD /Alert Exclusives

Researchers Address Potential Cardiotoxicity Concerns of Aromatase Inhibitors in Early Breast Cancer

Researchers Address Potential Cardiotoxicity Concerns of Aromatase Inhibitors in Early Breast Cancer

FDA Approves Tucatinib as Maintenance Therapy for HER2-Positive Breast Cancer

FDA Approves Tucatinib as Maintenance Therapy for HER2-Positive Breast Cancer

FDA Approves Palbociclib With Trastuzumab for HR-Positive, HER2-Positive MBC

FDA Approves Palbociclib With Trastuzumab for HR-Positive, HER2-Positive MBC

Rilvegostomig Plus Trastuzumab Deruxtecan Allows Certain Patients to Skip Breast Cancer Chemotherapy

Rilvegostomig Plus Trastuzumab Deruxtecan Allows Certain Patients to Skip Breast Cancer Chemotherapy

Real-World Analysis Suggests Lower Brain Metastasis Risk With T-DXd vs TTC in Patients With HER2+ Metastatic Breast Cancer

Real-World Analysis Suggests Lower Brain Metastasis Risk With T-DXd vs TTC in Patients With HER2+ Metastatic Breast Cancer

Sacituzumab Govitecan Improves PFS2 in Patients With Previously Untreated TNBC

Sacituzumab Govitecan Improves PFS2 in Patients With Previously Untreated TNBC

Weight-Loss Intervention Improves Physical Functioning, Quality of Life in Breast Cancer

Weight-Loss Intervention Improves Physical Functioning, Quality of Life in Breast Cancer

Bireociclib, Fulvestrant Improve PFS After Endocrine Therapy in Advanced Breast Cancer

Bireociclib, Fulvestrant Improve PFS After Endocrine Therapy in Advanced Breast Cancer

Exemestane Less Effective Than Other Aromatase Inhibitors for Postmenopausal BC Patients

Exemestane Less Effective Than Other Aromatase Inhibitors for Postmenopausal BC Patients

AI Tool Improves Accuracy, Reduces Equivocal Results in HER2 Breast Cancer Scoring

AI Tool Improves Accuracy, Reduces Equivocal Results in HER2 Breast Cancer Scoring

Imlunestrant, Abemaciclib Improve OS in Patients With Advanced Breast Cancer

Imlunestrant, Abemaciclib Improve OS in Patients With Advanced Breast Cancer

Parity and Breastfeeding Confer T-Cell Protection Against Breast Cancer

Parity and Breastfeeding Confer T-Cell Protection Against Breast Cancer

Adjuvant Chemotherapy Offers No Survival Benefit for Older Patients With Breast Cancer

Adjuvant Chemotherapy Offers No Survival Benefit for Older Patients With Breast Cancer

Ribociclib, Trastuzumab, Letrozole Combination Extends Survival in HR+/ HER2+ Advanced Breast Cancer

Ribociclib, Trastuzumab, Letrozole Combination Extends Survival in HR+/ HER2+ Advanced Breast Cancer

Model Predicts Future Risk of Breast Cancer Following ER+/HER2- Breast Cancer

Model Predicts Future Risk of Breast Cancer Following ER+/HER2- Breast Cancer

Sacituzumab Govitecan, Pembrolizumab Effective for Early Triple-Negative Breast Cancer

Sacituzumab Govitecan, Pembrolizumab Effective for Early Triple-Negative Breast Cancer

Black, Latinx, and Asian Women Less Likely to Receive Biomarker Testing Following Metastatic Breast Cancer Diagnosis

Black, Latinx, and Asian Women Less Likely to Receive Biomarker Testing Following Metastatic Breast Cancer Diagnosis

Elacestrant May Offer ‘Endocrine Therapy Backbone’ in ER+/ HER2- Breast Cancer

Elacestrant May Offer ‘Endocrine Therapy Backbone’ in ER+/ HER2- Breast Cancer

Combination Inavolisib, Palbociclib, Fulvestrant Boosts Survival for PIK3CA-Mutated HR+, HER2-, Endocrine-Resistant Advanced Breast Cancer

Combination Inavolisib, Palbociclib, Fulvestrant Boosts Survival for PIK3CA-Mutated HR+, HER2-, Endocrine-Resistant Advanced Breast Cancer

Artificial Intelligence Training Platform Aids in Better HER2 Immunohistochemistry Scoring

Artificial Intelligence Training Platform Aids in Better HER2 Immunohistochemistry Scoring

Certain Patients with Invasive Breast Cancer Can Achieve Long-Term Disease Control Without Surgery

Certain Patients with Invasive Breast Cancer Can Achieve Long-Term Disease Control Without Surgery

FDA Approves Trastuzumab Deruxtecan in Earlier Line of HER2-low, Ultralow Breast Cancer

FDA Approves Trastuzumab Deruxtecan in Earlier Line of HER2-low, Ultralow Breast Cancer

Reducing the Digital Burden in Cancer Care Delivery, Knowledge

Reducing the Digital Burden in Cancer Care Delivery, Knowledge

Sacituzumab Govitecan Improves Outcomes for Pretreated Triple-Negative Breast Cancer

Sacituzumab Govitecan Improves Outcomes for Pretreated Triple-Negative Breast Cancer

ASCO, SSO Publish Guidelines for Germline Mutation Testing in Breast Cancer

ASCO, SSO Publish Guidelines for Germline Mutation Testing in Breast Cancer

Less Frequent Mammography for Breast Cancer Survivors Has No Impact on Survival

Less Frequent Mammography for Breast Cancer Survivors Has No Impact on Survival

Fertility Preservation Safe for Patients Who Pause HR-positive Breast Cancer Endocrine Therapy to Conceive

Fertility Preservation Safe for Patients Who Pause HR-positive Breast Cancer Endocrine Therapy to Conceive

Patients with Breast Cancer That Converts from Lymph Node-Positive to -Negative Can Skip Adjuvant Irradiation

Patients with Breast Cancer That Converts from Lymph Node-Positive to -Negative Can Skip Adjuvant Irradiation

Tucatinib Plus Trastuzumab Emtansine Extend PFS in Late-Stage HER2-Positive Breast Cancer

Tucatinib Plus Trastuzumab Emtansine Extend PFS in Late-Stage HER2-Positive Breast Cancer

Younger Postmenopausal Patients May Skip Adjuvant Radiotherapy After Early Breast Cancer Surgery

Younger Postmenopausal Patients May Skip Adjuvant Radiotherapy After Early Breast Cancer Surgery

Sacituzumab Govitecan Improves OS in Endocrine-Resistant Metastatic Breast Cancer

Sacituzumab Govitecan Improves OS in Endocrine-Resistant Metastatic Breast Cancer

Pertuzumab, Trastuzumab Combination Effective in HER2+ Metastatic Breast Cancer

Pertuzumab, Trastuzumab Combination Effective in HER2+ Metastatic Breast Cancer

PET-CT Scanning Improves Detection of Metastases in Patients With Locally Advanced Breast Cancer

PET-CT Scanning Improves Detection of Metastases in Patients With Locally Advanced Breast Cancer

NCCN Clinical Practice Guidelines Recommend FES PET Imaging for ER+ Breast Cancer

NCCN Clinical Practice Guidelines Recommend FES PET Imaging for ER+ Breast Cancer

Featured Breast Cancer Videos

Neoadjuvant Opportunities in Early, High-Risk Breast Cancer

Neoadjuvant Opportunities in Early, High-Risk Breast Cancer

Integrating Tailored Therapy in Early, High-Risk Breast Cancer

Integrating Tailored Therapy in Early, High-Risk Breast Cancer

Providing Equitable Care in Early Breast Cancer

Providing Equitable Care in Early Breast Cancer

Going the Distance With Metastatic Breast Cancer: 'Personal Best'

Going the Distance With Metastatic Breast Cancer: "Personal Best"

Metastatic Breast Cancer: 'The Journey Begins'

Metastatic Breast Cancer: "The Journey Begins"

ASCO 2025 Annual Meeting

Ribociclib, Trastuzumab, Letrozole Combination Extends Survival in HR+/ HER2+ Advanced Breast Cancer

Ribociclib, Trastuzumab, Letrozole Combination Extends Survival in HR+/ HER2+ Advanced Breast Cancer

Model Predicts Future Risk of Breast Cancer Following ER+/HER2- Breast Cancer

Model Predicts Future Risk of Breast Cancer Following ER+/HER2- Breast Cancer

Sacituzumab Govitecan, Pembrolizumab Effective for Early Triple-Negative Breast Cancer

Sacituzumab Govitecan, Pembrolizumab Effective for Early Triple-Negative Breast Cancer

Black, Latinx, and Asian Women Less Likely to Receive Biomarker Testing Following Metastatic Breast Cancer Diagnosis

Black, Latinx, and Asian Women Less Likely to Receive Biomarker Testing Following Metastatic Breast Cancer Diagnosis

Elacestrant May Offer ‘Endocrine Therapy Backbone’ in ER+/ HER2- Breast Cancer

Elacestrant May Offer ‘Endocrine Therapy Backbone’ in ER+/ HER2- Breast Cancer

Artificial Intelligence Training Platform Aids in Better HER2 Immunohistochemistry Scoring

Artificial Intelligence Training Platform Aids in Better HER2 Immunohistochemistry Scoring

Combination Inavolisib, Palbociclib, Fulvestrant Boosts Survival for PIK3CA-Mutated HR+, HER2-, Endocrine-Resistant Advanced Breast Cancer

Combination Inavolisib, Palbociclib, Fulvestrant Boosts Survival for PIK3CA-Mutated HR+, HER2-, Endocrine-Resistant Advanced Breast Cancer

SABCS 2024 Annual Meeting

Sacituzumab Deruxtecan Improves Quality of Life in Patients with MBC

Sacituzumab Deruxtecan Improves Quality of Life in Patients with MBC

Circulating Tumor DNA May Independently Predict Survival Outcomes in MBC

Circulating Tumor DNA May Independently Predict Survival Outcomes in MBC

Trastuzumab Deruxtecan Improves Outcomes for Patients with Progression After Endocrine Therapy

Trastuzumab Deruxtecan Improves Outcomes for Patients with Progression After Endocrine Therapy

Certain Common Medications May Reduce Breast Cancer Risk

Certain Common Medications May Reduce Breast Cancer Risk

Adjuvant Endocrine Therapy Associated with Poor QoL in Older Patients with Early Breast Cancer

Adjuvant Endocrine Therapy Associated with Poor QoL in Older Patients with Early Breast Cancer

Reasons to Attend SABCS 2024 and How to Make the Most of It

Reasons to Attend SABCS 2024 and How to Make the Most of It

Looking Ahead to SABCS with Program Director Kate Lathrop, MD

Looking Ahead to SABCS with Program Director Kate Lathrop, MD

ASCO 2024 Annual Meeting

Certain Lymphocytes Indicate Treatment Responsive in Early HER2+ Breast Cancer

Certain Lymphocytes Indicate Treatment Responsive in Early HER2+ Breast Cancer

Country of Origin Impacts Breast Cancer Outcomes Among Hispanic Patients in US

Country of Origin Impacts Breast Cancer Outcomes Among Hispanic Patients in US

Intensive Chemotherapy Regimen Boosts Survival in TNBC Following Multigene Signature

Intensive Chemotherapy Regimen Boosts Survival in TNBC Following Multigene Signature

Datopotamab-Deruxtecan Delays Time to Deterioration Over Chemotherapy

Datopotamab-Deruxtecan Delays Time to Deterioration Over Chemotherapy

ASCO: Pregnancy, Live Birth Common After Breast Cancer Treatment

ASCO: Pregnancy, Live Birth Common After Breast Cancer Treatment

Highest Risk Luminal B-Type Tumors Have Poor Recurrence-Free Interval Rate

Highest Risk Luminal B-Type Tumors Have Poor Recurrence-Free Interval Rate

Hormone Receptor Positive Status Does Not Impact Prognosis in BRCA-Associated Early Breast Cancer

Hormone Receptor Positive Status Does Not Impact Prognosis in BRCA-Associated Early Breast Cancer

ASCO 2023 Annual Meeting

Donepezil Does Not Improve Cancer-Related Cognitive Impairment in Breast Cancer Survivors

Donepezil Does Not Improve Cancer-Related Cognitive Impairment in Breast Cancer Survivors

Breast Cancer Index Risk Scores a Prognostic Indicator of Overall, Late Distant Recurrence

Breast Cancer Index Risk Scores a Prognostic Indicator of Overall, Late Distant Recurrence

HER3-DXd Promotes Clinical Activity in MBC at Varying HER3 Expression Levels

HER3-DXd Promotes Clinical Activity in MBC at Varying HER3 Expression Levels

Capecitabine Has Less Toxicity, Similar Survival in Metastatic Breast Cancer with Fixed Dose

Capecitabine Has Less Toxicity, Similar Survival in Metastatic Breast Cancer with Fixed Dose

Greater Weight Loss Among Women with Breast Cancer After Phone-Based Coaching

Greater Weight Loss Among Women with Breast Cancer After Phone-Based Coaching

SABCS 2023 Annual Meeting

Less Frequent Mammography for Breast Cancer Survivors Has No Impact on Survival

Less Frequent Mammography for Breast Cancer Survivors Has No Impact on Survival

Fertility Preservation Safe for Patients Who Pause HR-positive Breast Cancer Endocrine Therapy to Conceive

Fertility Preservation Safe for Patients Who Pause HR-positive Breast Cancer Endocrine Therapy to Conceive

Patients with Breast Cancer That Converts from Lymph Node-Positive to -Negative Can Skip Adjuvant Irradiation

Patients with Breast Cancer That Converts from Lymph Node-Positive to -Negative Can Skip Adjuvant Irradiation

Tucatinib Plus Trastuzumab Emtansine Extend PFS in Late-Stage HER2-Positive Breast Cancer

Tucatinib Plus Trastuzumab Emtansine Extend PFS in Late-Stage HER2-Positive Breast Cancer

Younger Postmenopausal Patients May Skip Adjuvant Radiotherapy After Early Breast Cancer Surgery

Younger Postmenopausal Patients May Skip Adjuvant Radiotherapy After Early Breast Cancer Surgery